BFNH 10-Q Quarterly Report March 31, 2022 | Alphaminr
BIOFORCE NANOSCIENCES HOLDINGS, INC.
ALPHAMINR

BFNH 10-Q Quarter ended March 31, 2022

Balance Sheet
Cash Flow
Income Statement
CIK: 1310488
Filing Type: 10-Q/A
Report Date: 2022-03-31
Download URL: https://www.sec.gov/Archives/edgar/data/1310488/000109181822000045/bfnh-20220331.htm
]]>
TABLE OF CONTENTS
Part I Financial InformationItem 1. Financial StatementsNote 1 Organization & Description Of BusinessNote 2 Summary Of Significant Accounting PoliciesNote 2 Summary Of Significant Accounting Policies - ContinuedNote 3 Recently Issued Accounting StandardsNote 4 Going ConcernNote 5 Related Party TransactionsNote 6 StockNote 7 Risks and UncertaintiesItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPart II - Other InformationItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mining Safety DisclosuresItem 5. Other InformationItem 6. Exhibits

Exhibits

31.1+ Certification of Steve Gagnon Chief Executive Officer of Bravo Multinational Incorporated, pursuant to 18 U.S.C. 1350, as adopted pursuant to 302 of the Sarbanes-Oxley Act of 2002. 31.2+ Certification of Richard Kaiser, Chief Financial Officer and Principal Accounting Officer of Bravo Multinational Incorporated, pursuant to 18 U.S.C. 1350, as adopted pursuant to 302 of the Sarbanes-Oxley Act of 2002. 32.1+ Certification of Steve Gagnon Chief Executive Officer of Bravo Multinational Incorporated, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002. 32.2+ Certification of Richard Kaiser, Chief Financial Officer and Principal Accounting Officer of Bravo Multinational Incorporated, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002.